NFP Retirement Inc. Acquires 614 Shares of Pfizer Inc. (NYSE:PFE)

NFP Retirement Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 8.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,920 shares of the biopharmaceutical company’s stock after buying an additional 614 shares during the quarter. NFP Retirement Inc.’s holdings in Pfizer were worth $210,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Passumpsic Savings Bank grew its stake in Pfizer by 8.4% in the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company’s stock worth $743,000 after buying an additional 1,998 shares in the last quarter. Virtu Financial LLC bought a new position in Pfizer during the 3rd quarter worth approximately $1,499,000. Westside Investment Management Inc. increased its stake in shares of Pfizer by 7.7% in the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company’s stock worth $404,000 after buying an additional 1,004 shares during the period. Diamant Asset Management Inc. increased its position in shares of Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 660 shares during the period. Finally, Morse Asset Management Inc bought a new position in Pfizer during the 3rd quarter valued at approximately $2,649,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 1.4 %

Shares of Pfizer stock opened at $21.89 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a fifty day moving average of $25.25 and a 200 day moving average of $26.40. The company has a market capitalization of $124.14 billion, a P/E ratio of 15.52, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the company posted $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PFE. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. UBS Group decreased their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.07.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.